Literature DB >> 17417999

Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab.

R Almodóvar1, M Izquierdo, P Zarco, F Javier Quirós, R Mazzucchelli, B Steen.   

Abstract

We present a case of a 34 year-old male diagnosed with ankylosing spondylitis. After two years of treatment with infliximab, the patient developed a clinical picture compatible with stage II thoracic sarcoidosis. These findings resulted in the interruption of infliximab therapy. The patient was not administered new treatment since respiratory function testing did not confirm harmful repercussions. After a follow-up of 1 year, the patient is asymptomatic and radiologic tests show complete resolution of pulmonary infiltrates and mediastinal and bilateral hilar lymphad- enopathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17417999

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  15 in total

Review 1.  A concise review of pulmonary sarcoidosis.

Authors:  Robert P Baughman; Daniel A Culver; Marc A Judson
Journal:  Am J Respir Crit Care Med       Date:  2010-10-29       Impact factor: 21.405

2.  Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab.

Authors:  Peter Korsten; Nadera J Sweiss; Ulf Nagorsnik; Timothy B Niewold; Hermann-Josef Gröne; Oliver Gross; Gerhard A Müller
Journal:  Am J Kidney Dis       Date:  2010-10-25       Impact factor: 8.860

Review 3.  Sarcoid-like granulomatosis in patients treated with anti-TNFα factors. A case report and review of the literature.

Authors:  Theoni Kanellopoulou; Anna Filiotou; Hariklia Kranidioti; Spyridon P Dourakis
Journal:  Clin Rheumatol       Date:  2010-10-23       Impact factor: 2.980

4.  Sarcoidosis with ankylosing spondylitis: changing therapeutic landscape.

Authors:  Chinnabhathini Deva Rahul; Rahul Kumar Sharma; Deepak Talwar
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

5.  Refractory multisystem sarcoidosis responding to infliximab therapy.

Authors:  Adam P Croft; Deva Situnayake; Omer Khair; Gavin Giovanni; David Carruthers; Arul Sivaguru; Caroline Gordon
Journal:  Clin Rheumatol       Date:  2012-01-17       Impact factor: 2.980

6.  Tumor necrosis factor-alpha (TNF-α)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature.

Authors:  Raquel Cuchacovich; Joseph Hagan; Tahir Khan; Arthur Richert; Luis R Espinoza
Journal:  Clin Rheumatol       Date:  2010-10-01       Impact factor: 2.980

Review 7.  Pulmonary complications of tumor necrosis factor-targeted therapy.

Authors:  Krishna Thavarajah; Peggy Wu; Elisa J Rhew; Anjana K Yeldandi; David W Kamp
Journal:  Respir Med       Date:  2009-02-07       Impact factor: 3.415

8.  Update on bioagent therapy in sarcoidosis.

Authors:  Vincent Cottin
Journal:  F1000 Med Rep       Date:  2010-02-24

Review 9.  Evidence-based therapy for cutaneous sarcoidosis.

Authors:  Christy B Doherty; Ted Rosen
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Development of sarcoidosis following etanercept treatment: a report of three cases.

Authors:  Inger Marie Skoie; Klaus Wildhagen; Roald Omdal
Journal:  Rheumatol Int       Date:  2010-01-09       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.